2012 – A good year for pharmaceutical innovation

In the USA the number of new drugs authorized by the FDA reached a new high, with 39 market authorizations. And in Europe the EMA authorized 52 new drugs. The European Agency is expecting a better result in 2013 with 64 new drugs, including 20 orphan drugs and 20 generics. These are encouraging results as most of these drugs are new molecular entities (NME) that have never previously been used in a treatment.